The content, links, and pdfs are no longer maintained and might be outdated.
- The content on this page is being archived for historic and reference purposes only.
- For current, updated information see the MMWR website.
Errata:: Vol. 59, No. 20
In the report "FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)," the second footnote under Table 2 should read as follows: "Phase III trial. According to protocol efficacy analysis included females aged 15 through 25 years who received all 3 vaccine doses, were seronegative at day 1 and HPV DNA negative at day 1 through month 6 for the respective HPV type, and had normal or low grade cytology at day 1, with case counting beginning 1 day after third vaccine dose; mean duration of follow-up post third vaccine dose: 34.9 months."
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to email@example.com.